References
Acevedo-Whitehouse, K., & Bruno, R. (2023). Potential health risks of mRNA-based vaccine therapy: A hypothesis. Medical Hypotheses, 171, 111015. https://doi.org/10.1016/j.mehy.2023.111015
Altman, N. L., Berning, A. A., Mann, S. C., Quaife, R. A., Gill, E. A., Auerbach, S. R., Campbell, T. B., & Bristow, M. R. (2023). Vaccination-Associated myocarditis and myocardial injury. Circulation Research, 132(10), 1338–1357. https://doi.org/10.1161/circresaha.122.321881
Balagurunathan, Y., & Sethuraman, R. R. (2024). An analysis of Ethics-Based Foundation and Regulatory Issues for Genomic Data Privacy. Journal of the Institution of Engineers (India) Series B, 105(4), 1097–1107. https://doi.org/10.1007/s40031-024-01058-3
Banoun, H. (2023). MRNA: vaccine or gene therapy? The safety regulatory issues. International Journal of Molecular Sciences, 24(13), 10514. https://doi.org/10.3390/ijms241310514
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 20(11), 817–838. https://doi.org/10.1038/s41573-021-00283-5
Córdoba, K. M., Jericó, D., Sampedro, A., Jiang, L., Iraburu, M. J., Martini, P. G., Berraondo, P., Avila, M. A., & Fontanellas, A. (2022). Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases. International Review of Cell and Molecular Biology, 55–96. https://doi.org/10.1016/bs.ircmb.2022.03.005
Cusumano, M. A. (2024, May 1). How pharmaceutical companies utilize platform Strategy: A study of the COVID-19 mRNA vaccine development. https://dspace.mit.edu/handle/1721.1/155647
De Souza, A. S., De Freitas Amorim, V. M., Guardia, G. D. A., Santos, F. F. D., Ulrich, H., Galante, P. a. F., De Souza, R. F., & Guzzo, C. R. (2022). Severe Acute Respiratory Syndrome Coronavirus 2 Variants of concern: A perspective for emerging More Transmissible and Vaccine-Resistant Strains. Viruses, 14(4), 827. https://doi.org/10.3390/v14040827
Dórea, J. G. (2008). Persistent, bioaccumulative and toxic substances in fish: Human health considerations. The Science of the Total Environment, 400(1–3), 93–114. https://doi.org/10.1016/j.scitotenv.2008.06.017
Dwivedi, S., Purohit, P., Misra, R., Pareek, P., Goel, A., Khattri, S., Pant, K. K., Misra, S., & Sharma, P. (2017). Diseases and Molecular Diagnostics: a step closer to precision medicine. Indian Journal of Clinical Biochemistry, 32(4), 374–398. https://doi.org/10.1007/s12291-017-0688-8
Fine, P. E. M., & Zell, E. R. (1994). Outbreaks in Highly vaccinated populations: Implications for studies of vaccine performance. American Journal of Epidemiology, 139(1), 77–90. https://doi.org/10.1093/oxfordjournals.aje.a116937
Ghosh, A., Larrondo-Petrie, M. M., & Pavlovic, M. (2023). Revolutionizing Vaccine Development for COVID-19: A review of AI-Based Approaches. Information, 14(12), 665. https://doi.org/10.3390/info14120665
Ginsburg, G. S., & Willard, H. F. (2009). Genomic and personalized medicine: foundations and applications. Translational Research, 154(6), 277–287. https://doi.org/10.1016/j.trsl.2009.09.005
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023). A comprehensive review of mRNA vaccines. International Journal of Molecular Sciences, 24(3), 2700. https://doi.org/10.3390/ijms24032700
Hilleman, M. R. (2004). Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proceedings of the National Academy of Sciences, 101(suppl_2), 14560–14566. https://doi.org/10.1073/pnas.0404758101
Ji, P., Li, Y., Wang, Z., Jia, S., Jiang, X., Chen, H., & Wang, Q. (2024). Advances in precision gene editing for liver fibrosis: From technology to therapeutic applications. Biomedicine & Pharmacotherapy, 177, 117003. https://doi.org/10.1016/j.biopha.2024.117003
Mandel, L. (2024). Autoimmune disease. In Springer eBooks (pp. 115–142). https://doi.org/10.1007/978-3-031-50012-1_7
Moore, J. P., & Klasse, P. J. (2020). COVID-19 vaccines: “Warp speed” needs mind melds, not warped minds. Journal of Virology, 94(17). https://doi.org/10.1128/jvi.01083-20
Mueller, S. (2023). Challenges and opportunities of mRNA vaccines against SARS-COV-2. In Springer eBooks. https://doi.org/10.1007/978-3-031-18903-6
Muñoz-Carrillo, J. L., Castro-García, F. P., Chávez-Rubalcaba, F., Chávez-Rubalcaba, I., Martínez-Rodríguez, J. L., & Hernández-Ruiz, M. E. (2018). Immune system disorders: hypersensitivity and autoimmunity. In InTech eBooks. https://doi.org/10.5772/intechopen.75794
Pilati, F. (2024, May 20). One pandemic, many controversies. Mapping the COVID-19 “infodemic” via digital methods. https://tesidottorato.depositolegale.it/handle/20.500.14242/62066
Qin, Z., Bouteau, A., Herbst, C., & Igyártó, B. Z. (2022). Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion. PLoS Pathogens, 18(9), e1010830. https://doi.org/10.1371/journal.ppat.1010830
Rana, M. S., Das, S. S., Hossian, M., & Bashir, M. S. (2023). Impact and challenges of digital marketing in health care during the COVID-19 pandemic. Journal of Primeasia, 4(1), 1-4. https://doi.org/10.25163/primeasia.419756
Rehman, S. (2024, April 30). Ethical Implications of Genetic Engineering: Balancing innovation and responsibility. https://sprcopen.org/FBG/article/view/69
Roos, D., & De Boer, M. (2021). Mutations in cis that affect mRNA synthesis, processing and translation. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease, 1867(9), 166166. https://doi.org/10.1016/j.bbadis.2021.166166
Sajid, M., Ilyas, M., Basheer, C., Tariq, M., Daud, M., Baig, N., & Shehzad, F. (2014). Impact of nanoparticles on human and environment: review of toxicity factors, exposures, control strategies, and future prospects. Environmental Science and Pollution Research, 22(6), 4122–4143. https://doi.org/10.1007/s11356-014-3994-1
Samir, S. (2023). Human DNA Mutations and their Impact on Genetic Disorders. Recent Patents on Biotechnology, 18(4), 288–315. https://doi.org/10.2174/0118722083255081231020055309
Seneff, S., & Nigh, G. (2021). Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. International Journal of Vaccine Theory Practice and Research, 2(1), 38–79. https://doi.org/10.56098/ijvtpr.v2i1.23
Shmulevich, R., & Krizhanovsky, V. (2020). Cell senescence, DNA damage, and metabolism. Antioxidants and Redox Signaling, 34(4), 324–334. https://doi.org/10.1089/ars.2020.8043
Skerritt, J. H. (2025). Considerations for mRNA product development, regulation and deployment across the lifecycle. Vaccines, 13(5), 473. https://doi.org/10.3390/vaccines13050473
Stati, G., Amerio, P., Nubile, M., Sancilio, S., Rossi, F., & Di Pietro, R. (2023). Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery. International Journal of Molecular Sciences, 24(2), 1404. https://doi.org/10.3390/ijms24021404
Strianese, O., Rizzo, F., Ciccarelli, M., Galasso, G., D’Agostino, Y., Salvati, A., Del Giudice, C., Tesorio, P., & Rusciano, M. R. (2020). Precision and Personalized Medicine: How Genomic approach Improves the Management of cardiovascular and Neurodegenerative Disease. Genes, 11(7), 747. https://doi.org/10.3390/genes11070747
Thi, H. V., Thi, L. N., Tang, T. L., & Chu, D. (2024). Biosafety and regulatory issues of RNA therapeutics. Progress in Molecular Biology and Translational Science, 311–329. https://doi.org/10.1016/bs.pmbts.2023.12.008
Tufael, M.?S.?B., Rana, M.?S., Das, S.?S., & Hossian, M. (2023). Nutritional evaluation of cassava meal components. Journal of Primeasia, 4(1), 1–4. https://doi.org/10.25163/angiotherapy.839572\
Wallis, J., Shenton, D. P., & Carlisle, R. C. (2019). Novel approaches for the design, delivery and administration of vaccine technologies. Clinical & Experimental Immunology, 196(2), 189–204. https://doi.org/10.1111/cei.13287
Weerarathna, I. N., Kumar, P., Luharia, A., & Mishra, G. (2024). Engineering with Biomedical Sciences Changing the Horizon of Healthcare-A Review. Bioengineered, 15(1). https://doi.org/10.1080/21655979.2024.2401269
Xu, S., Yang, K., Li, R., & Zhang, L. (2020). MRNA Vaccine Era—Mechanisms, drug platform and Clinical Prospection. International Journal of Molecular Sciences, 21(18), 6582. https://doi.org/10.3390/ijms21186582
Zinkernagel, R. M. (2003). On natural and artificial vaccinations. Annual Review of Immunology, 21(1), 515–546. https://doi.org/10.1146/annurev.immunol.21.120601.141045